FDA Approves New Drug for Geographic Atrophy
The FDA has approved SYFOVRE, which is the first and only treatment for geographic atrophy, a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide.
Geographic atrophy is an advanced stage of dry age-related macular degeneration (AMD) in which cells of the retina and retinal pigment epithelial atrophy, eventually leading to cell death. Before SYFOVRE was approved, there were no treatments available for geographic atrophy, making the new medication one of the most important opthalmological care breakthroughs in recent years.
SYFOVRE was approved based on the OAKS and DERBY clinical trials, which were conducted over a period of 24 months. The medication showed that it was able to slow the progression of geographic atrophy with increased progression over time.